Trials / Completed
CompletedNCT04384081
A Study to Test How Different Doses of BI 456906 Are Tolerated in Japanese Men With a Body Mass Index (BMI) Between 23 and 40 kg/m2
A Phase I, Single-blinded, Randomized, Multiple Dose, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Different Dose Escalation Schemes of BI 456906 in Healthy Japanese Male Subject With BMI 23-40 kg/m2
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 37 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- Male
- Age
- 20 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
Main objectives are to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of different dose escalation schemes of BI 456906 in healthy Japanese male subject with BMI 23-40 kg/m2 and to determine a dose escalation scheme for future studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BI 456906 | Solution for injection |
| DRUG | Placebo | Solution for injection |
Timeline
- Start date
- 2020-06-01
- Primary completion
- 2020-11-17
- Completion
- 2021-01-20
- First posted
- 2020-05-12
- Last updated
- 2021-01-26
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT04384081. Inclusion in this directory is not an endorsement.